Abingdon HealthABDXF +11.07%49 Net Current Asset Value is $0.01 as of Dec. 2025, which is 100% below its 10-year median of 6.40. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.24 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 74.75% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Abingdon Health's net current asset value per share for the quarter that ended in Dec. 2025 was $0.01.
The historical rank and industry rank for Abingdon Health's Net Current Asset Value or its related term are showing as below:
ABDXF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.75 Med: 6.4 Max: 13.5
Current: 13.5
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Abingdon Health was 13.50. The lowest was 2.75. And the median was 6.40.
ABDXF's Price-to-Net-Current-Asset-Value is ranked worse than 74.75% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.82
vs ABDXF: 13.50
Abingdon Health (OTCPK:ABDXF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Abingdon Health Net Current Asset Value Related Terms
Abingdon Health Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
Abingdon Health (ABDXF) has a Net Current Asset Value of $0.01 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Abingdon Health and its competitors. This is 100% below median its historical median of 6.40. Over the past decade, Abingdon Health's Net Current Asset Value has ranged from 2.75 to 13.50. According to the industry distribution chart, Abingdon Health ranks #74 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 74.7%.
Is Abingdon Health's Net Current Asset Value too high?
Abingdon Health's current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 6.40. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 13.50. The Medical Diagnostics & Research industry median Net Current Asset Value is 3.82. Abingdon Health's value of $0.01 is 99.7% below this industry median. Based on the distribution chart, Abingdon Health ranks #74 out of 99 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #74 out of 99 companies for Net Current Asset Value. This places Abingdon Health in the lower half of its industry. The industry median Net Current Asset Value is 3.82. Abingdon Health's value of $0.01 is 99.7% below this benchmark. Historically, Abingdon Health's own Net Current Asset Value has ranged from 2.75 to 13.50 over the past decade. While the company's 10-year median is 6.40 vs. the industry median of 3.82, Abingdon Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.82, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Net Current Asset Value of $0.01 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 6.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 43.8% below its estimated fair value. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 6.40 and 99.7% below the Medical Diagnostics & Research industry median of 3.82. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Net Current Asset Value is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 43.8% below its estimated GF Value™ of $0.24.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
Net Current Asset Value: $0.01 (100% below median its 10-year median of 6.40)
GF Value™: $0.24 vs. price of $0.14 (43.8% below fair value)
Industry Position: 99.7% below the Medical Diagnostics & Research median (#74 of 99)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
